MultiCell Technologies, Inc. engages in the development of biopharmaceutical drugs for the treatment of autoimmune diseases, including multiple sclerosis, type-1 diabetes, influenza and other health threats. The company also produces immortalized human hepatocyte cell lines used in the development of new therapeutics.